Literature DB >> 17683170

Current management of mantle cell lymphoma.

Oliver Weigert1, Michael Unterhalt, Wolfgang Hiddemann, Martin Dreyling.   

Abstract

Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal antibodies and dose-intensified regimens, including autologous and allogeneic stem cell transplantation strategies, the prognosis remains particularly poor. Recently gained insights into the underlying biology and pathogenesis have unravelled numerous promising molecular targeting strategies; however, their introduction into clinical practice and current treatment algorithms remains a challenge. This article addresses these issues providing relevant information for current state-of-the-art management of patients with mantle cell lymphoma and giving a perspective of upcoming treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683170     DOI: 10.2165/00003495-200767120-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  86 in total

1.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Authors:  Robert Z Orlowski; Thomas E Stinchcombe; Beverly S Mitchell; Thomas C Shea; Albert S Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J Elliott; Christine S Pien; Roberto Guerciolini; Jessica K Anderson; Natalie D Depcik-Smith; Rita Bhagat; Mary Jo Lehman; Steven C Novick; Owen A O'Connor; Steven L Soignet
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

2.  Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy.

Authors:  N Kröger; M Hoffknecht; P Dreger; W Krüger; W Zeller; A Krüll; M Stockschläder; S Bittner; H J Weh; A R Zander
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

3.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.

Authors:  K C Anderson; M P Bates; B L Slaughenhoupt; G S Pinkus; S F Schlossman; L M Nadler
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

Review 4.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

Authors:  Chikashi Nakanishi; Masakazu Toi
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

Authors:  Alessandro M Gianni; Michele Magni; Maurizio Martelli; Massimo Di Nicola; Carmelo Carlo-Stella; Silvana Pilotti; Alessandro Rambaldi; Sergio Cortelazzo; Caterina Patti; Guido Parvis; Fabio Benedetti; Saveria Capria; Paolo Corradini; Corrado Tarella; Tiziano Barbui
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

Review 6.  Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group.

Authors:  D D Weisenburger; J M Vose; T C Greiner; J C Lynch; W C Chan; P J Bierman; B J Dave; W G Sanger; J O Armitage
Journal:  Am J Hematol       Date:  2000-07       Impact factor: 10.047

7.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  C Tom Kouroukis; Andrew Belch; Michael Crump; Elizabeth Eisenhauer; Randy D Gascoyne; Ralph Meyer; Reinhard Lohmann; Pedro Lopez; Jean Powers; Robert Turner; Joseph M Connors
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

Review 8.  The role of fludarabine in the treatment of follicular and mantle cell lymphoma.

Authors:  Georg Lenz; Wolfgang Hiddemann; Martin Dreyling
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

9.  Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.

Authors:  J Mangel; H A Leitch; J M Connors; R Buckstein; K Imrie; D Spaner; M Crump; N Pennell; A Boudreau; N L Berinstein
Journal:  Ann Oncol       Date:  2004-02       Impact factor: 32.976

10.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Authors:  John F DiJoseph; Douglas C Armellino; Erwin R Boghaert; Kiran Khandke; Maureen M Dougher; Latha Sridharan; Arthur Kunz; Philip R Hamann; Boris Gorovits; Chandrasekhar Udata; Justin K Moran; Andrew G Popplewell; Sue Stephens; Philip Frost; Nitin K Damle
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

View more
  2 in total

1.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

Review 2.  Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.

Authors:  Sheridan M Hoy; Kate McKeage
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.